Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...

In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...

As Massachusetts prepares to vote on a measure that would legalize psilocybin and other plant-based psychedelic substances, ...

Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the ...

Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.

Lykos Therapeutics is slashing around 75% of its staff following the FDA's decision not to approve its MDMA-assisted therapy for post-traumatic stress disorder (PTSD) last week, with founder Rick ...

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

T he Food and Drug Administration (FDA) declined on Friday to approve MDMA-assisted psychotherapy as a treatment for ...

The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...

Why Harris-Walz? The women say they believe Donald Trump, the Republican candidate, would reduce funding for Medicaid and Medicare spending and repeal the Affordable Care Act. They say that would ...

“As someone who’s spoken to people who have had their lives saved due to MDMA-therapy, the FDA’s decision to deny Lykos’ application comes as a great disappointment,” said Kat ...

Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug ...